Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 51, Issue SUPPL.4, 2012, Pages

  Jacobs, Johannes W G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anchor drug; Glucocorticoids; Methotrexate; Prednisone; Rheumatoid arthritis; Tight control; Treat to target

Indexed keywords

CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PROTOCOL; DAS 28; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; JOINT INJURY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; EUROPE; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84862670760     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes083     Document Type: Article

References (42)

1. Bensen WG, Bensen W, Adachi JD, Tugwell PX. Remodelling the pyramid: the therapeutic target of rheumatoid arthritis. J Rheumatol 1990;17:987-9.
2. Hess EV, Luggen ME. Remodeling the pyramid-a concept whose time has not yet come. J Rheumatol 1989;16: 1175-6.
3. Malleson PN, Petty RE. Remodelling the pyramid-a pediatric prospective. J Rheumatol 1990;17:867-8.
4. McCarty DJ. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J Rheumatol 1990;17: 1115-8.
5. Sokka T. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010;28(Suppl. 61):S13-20.
6. Gorter SL, Bijlsma JW, Cutolo M et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
7. Gaujoux-Viala C, Smolen JS, Landewé R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
8. Knevel R, Schoels M, Huizinga TWJ et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987-94.
9. Nam JL, Winthrop KL, van Vollenhoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
10. Schoels M, Wong J, Scott DL et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
11. Smolen JS, Landewé R, Breeveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
12. Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 2000;39: 603-11.
13. Bakker MF, Jacobs JW, Welsing PM et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011;70:1099-103.
14. Bakker MF, Jacobs JWG, Welsing PM et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. A randomized trial. Ann Intern Med 2012;156:329-39.
15. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48: 1771-4.
16. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
17. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21(5 Suppl. 31):S154-7.
18. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
19. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum 2010;62: 2569-81.
20. Bakker MF, Jacobs JWG, Kruize AA et al. Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices which do not include joints of feet. Ann Rheum Dis 2011, Advance Access published 29 November 2011, doi:10.1136/annrheumdis-2011-146670.
21. Lee YC, Cui J, Lu B et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011;13:R83.
22. Rezaei H, van Vollenhoven RF, Forslind K et al. Radiological progression in patients with early RA and a good clinical response to MTX monotherapy: predictors and clinical implications. Ann Rheum Dis 2010; 69(Suppl. 3):64.
23. Wallin H, van Vollenhoven RF, Albertsson K et al. In early RA, patients with a good initial response to MTX monotherapy have excellent clinical outcomes over two years of therapy but radiological progression is not completely prevented. Ann Rheum Dis 2010;69(Suppl. 3):212.
24. Ton E, Bakker MF, Verstappen SMM et al. Look beyond the DAS28: tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol 2012;39:22-7.
25. Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
26. Schoels M, Knevel R, Aletaha D et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69: 638-43.
27. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404-13.
28. Huscher D, Thiele K, Bischoff S et al. Performance of the new ACR/EULAR remission criteria compared to DAS28 remission in unselected real-life patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl. 3):178.
29. Vermeer M, Kuper H, van der Bijl A et al. The new ACR/ EULAR definition of remission in rheumatoid arthritis: is the patient global assessment criterion too strict? Ann Rheum Dis 2011;70(Suppl. 3):178.
30. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63.
31. Bijlsma JW, Jacobs JW. Methotrexate: still the anchor drug in RA treatment. Joint Bone Spine 2009;76:452-4.
32. Jurgens MS, Jacobs JWG, Bijlsma JWJ. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol 2011;25: 523-33.
33. Bakker MF, Jacobs JW, Welsing PM et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010;69: 1849-52.
34. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
35. Lipsky PE, van der Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
36. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol 2010; 28(Suppl. 61):S52-7.
37. Kirwan J, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;4:CD006356.
38. van Tuyl LHD, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69:807-12.
39. Bijlsma JWJ, Hoes JN, van Everdingen AA, Verstappen SMM, Jacobs JWG. Are glucocorticoids DMARDs? Ann N Y Acad Sci 2006;1069:268-74.
40. Alten RHE. Clinical trials: insufficient data on glucocorticoid use in RA trials. Nat Rev Rheumatol 2011;7: 318-9.
41. da Silva JAP, Jacobs JWG, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
42. Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology 2009;48:807-11.